Cargando…

Impact of vaccination on the symptoms of hospitalised patients with SARS-CoV-2 Delta variant (B.1.617.1) infection

OBJECTIVES: The diffusion of the SARS-CoV-2 Delta (B.1.617.2) variant and the waning of immune response after primary Covid-19 vaccination favoured the breakthrough SARS-CoV-2 infections in vaccinated subjects. To assess the impact of vaccination, we determined the severity of infection in hospitali...

Descripción completa

Detalles Bibliográficos
Autores principales: Epaulard, Olivier, Abgrall, Sophie, Lefebvre, Maeva, Faucher, Jean-François, Michon, Jocelyn, Frentiu, Emilia, Blanchi, Sophie, Janssen, Cécile, Charbonnier, Gabrielle, Fresse, Audrey, Laurent, Simon, Sandjakian, Lena, Casez, Pierre, Mahamat, Aba, Beraud, Guillaume
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9242694/
https://www.ncbi.nlm.nih.gov/pubmed/35779764
http://dx.doi.org/10.1016/j.cmi.2022.06.019
_version_ 1784738107434729472
author Epaulard, Olivier
Abgrall, Sophie
Lefebvre, Maeva
Faucher, Jean-François
Michon, Jocelyn
Frentiu, Emilia
Blanchi, Sophie
Janssen, Cécile
Charbonnier, Gabrielle
Fresse, Audrey
Laurent, Simon
Sandjakian, Lena
Casez, Pierre
Mahamat, Aba
Beraud, Guillaume
author_facet Epaulard, Olivier
Abgrall, Sophie
Lefebvre, Maeva
Faucher, Jean-François
Michon, Jocelyn
Frentiu, Emilia
Blanchi, Sophie
Janssen, Cécile
Charbonnier, Gabrielle
Fresse, Audrey
Laurent, Simon
Sandjakian, Lena
Casez, Pierre
Mahamat, Aba
Beraud, Guillaume
author_sort Epaulard, Olivier
collection PubMed
description OBJECTIVES: The diffusion of the SARS-CoV-2 Delta (B.1.617.2) variant and the waning of immune response after primary Covid-19 vaccination favoured the breakthrough SARS-CoV-2 infections in vaccinated subjects. To assess the impact of vaccination, we determined the severity of infection in hospitalised patients according to vaccine status. METHODS: We performed a retrospective observational study on patients hospitalised in 10 centres with a SARS-CoV-2 infection (Delta variant) from July to November 2021 by including all patients who had completed their primary vaccination at least 14 days before hospital admission and the same number of completely unvaccinated patients. We assessed the impact of vaccination and other risk factors through logistic regression. RESULTS: We included 955 patients (474 vaccinated and 481 unvaccinated). Vaccinated patients were significantly older (75.0 [63.25-84.0] vs. 55.0 [38.0-73.0]; p < 0.001), more frequently males (55.1% (261/474) vs. 46.4% (223/481); p = 0.009), and had more comorbidities (2.0 [1.0-3.0] vs. 1.0 [0.0-2.0]; p < 0.001). Vaccinated patients were less often admitted for Covid-19 (59.3% (281/474) vs. 75.1% (361/481); p < 0.001), had less extended lung lesions (≤25%: 64.3% (117/182) vs. 38.4% (88/229); p < 0.001), required oxygen less frequently (57.5% (229/398) vs. 73.0% (270/370); p < 0.001), at a lower flow (3.0 [0.0-8.7] vs. 6.0 [2.0-50.0] L/min, p < 0.001), and for a shorter duration (3 [0.0-8.0] vs. 6 [2.0-12.0] days, p < 0.001)., and required less frequently intensive care unit admission (16.2% (60/370) vs. 36.0% (133/369); p < 0.001) but had comparable mortality in bivariate analysis (16.7% (74/443) vs. 12.2% (53/433); p = 0.075). Multivariate logistic regression showed that vaccination significantly decreased the risk of death (0.38 [0.20-0.70](p = 0.002), ICU admission (0.31 [0.21-0.47](p < 0.001) and oxygen requirement (0.16 [0.10-0.26](p < 0.001), even among older patients or with comorbidities. CONCLUSIONS: Among patients hospitalised with a delta variant SARS-CoV-2 infection, vaccination was associated with less severe forms, even in the presence of comorbidities.
format Online
Article
Text
id pubmed-9242694
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-92426942022-06-30 Impact of vaccination on the symptoms of hospitalised patients with SARS-CoV-2 Delta variant (B.1.617.1) infection Epaulard, Olivier Abgrall, Sophie Lefebvre, Maeva Faucher, Jean-François Michon, Jocelyn Frentiu, Emilia Blanchi, Sophie Janssen, Cécile Charbonnier, Gabrielle Fresse, Audrey Laurent, Simon Sandjakian, Lena Casez, Pierre Mahamat, Aba Beraud, Guillaume Clin Microbiol Infect Original Article OBJECTIVES: The diffusion of the SARS-CoV-2 Delta (B.1.617.2) variant and the waning of immune response after primary Covid-19 vaccination favoured the breakthrough SARS-CoV-2 infections in vaccinated subjects. To assess the impact of vaccination, we determined the severity of infection in hospitalised patients according to vaccine status. METHODS: We performed a retrospective observational study on patients hospitalised in 10 centres with a SARS-CoV-2 infection (Delta variant) from July to November 2021 by including all patients who had completed their primary vaccination at least 14 days before hospital admission and the same number of completely unvaccinated patients. We assessed the impact of vaccination and other risk factors through logistic regression. RESULTS: We included 955 patients (474 vaccinated and 481 unvaccinated). Vaccinated patients were significantly older (75.0 [63.25-84.0] vs. 55.0 [38.0-73.0]; p < 0.001), more frequently males (55.1% (261/474) vs. 46.4% (223/481); p = 0.009), and had more comorbidities (2.0 [1.0-3.0] vs. 1.0 [0.0-2.0]; p < 0.001). Vaccinated patients were less often admitted for Covid-19 (59.3% (281/474) vs. 75.1% (361/481); p < 0.001), had less extended lung lesions (≤25%: 64.3% (117/182) vs. 38.4% (88/229); p < 0.001), required oxygen less frequently (57.5% (229/398) vs. 73.0% (270/370); p < 0.001), at a lower flow (3.0 [0.0-8.7] vs. 6.0 [2.0-50.0] L/min, p < 0.001), and for a shorter duration (3 [0.0-8.0] vs. 6 [2.0-12.0] days, p < 0.001)., and required less frequently intensive care unit admission (16.2% (60/370) vs. 36.0% (133/369); p < 0.001) but had comparable mortality in bivariate analysis (16.7% (74/443) vs. 12.2% (53/433); p = 0.075). Multivariate logistic regression showed that vaccination significantly decreased the risk of death (0.38 [0.20-0.70](p = 0.002), ICU admission (0.31 [0.21-0.47](p < 0.001) and oxygen requirement (0.16 [0.10-0.26](p < 0.001), even among older patients or with comorbidities. CONCLUSIONS: Among patients hospitalised with a delta variant SARS-CoV-2 infection, vaccination was associated with less severe forms, even in the presence of comorbidities. European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. 2022-12 2022-06-30 /pmc/articles/PMC9242694/ /pubmed/35779764 http://dx.doi.org/10.1016/j.cmi.2022.06.019 Text en © 2022 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Original Article
Epaulard, Olivier
Abgrall, Sophie
Lefebvre, Maeva
Faucher, Jean-François
Michon, Jocelyn
Frentiu, Emilia
Blanchi, Sophie
Janssen, Cécile
Charbonnier, Gabrielle
Fresse, Audrey
Laurent, Simon
Sandjakian, Lena
Casez, Pierre
Mahamat, Aba
Beraud, Guillaume
Impact of vaccination on the symptoms of hospitalised patients with SARS-CoV-2 Delta variant (B.1.617.1) infection
title Impact of vaccination on the symptoms of hospitalised patients with SARS-CoV-2 Delta variant (B.1.617.1) infection
title_full Impact of vaccination on the symptoms of hospitalised patients with SARS-CoV-2 Delta variant (B.1.617.1) infection
title_fullStr Impact of vaccination on the symptoms of hospitalised patients with SARS-CoV-2 Delta variant (B.1.617.1) infection
title_full_unstemmed Impact of vaccination on the symptoms of hospitalised patients with SARS-CoV-2 Delta variant (B.1.617.1) infection
title_short Impact of vaccination on the symptoms of hospitalised patients with SARS-CoV-2 Delta variant (B.1.617.1) infection
title_sort impact of vaccination on the symptoms of hospitalised patients with sars-cov-2 delta variant (b.1.617.1) infection
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9242694/
https://www.ncbi.nlm.nih.gov/pubmed/35779764
http://dx.doi.org/10.1016/j.cmi.2022.06.019
work_keys_str_mv AT epaulardolivier impactofvaccinationonthesymptomsofhospitalisedpatientswithsarscov2deltavariantb16171infection
AT abgrallsophie impactofvaccinationonthesymptomsofhospitalisedpatientswithsarscov2deltavariantb16171infection
AT lefebvremaeva impactofvaccinationonthesymptomsofhospitalisedpatientswithsarscov2deltavariantb16171infection
AT faucherjeanfrancois impactofvaccinationonthesymptomsofhospitalisedpatientswithsarscov2deltavariantb16171infection
AT michonjocelyn impactofvaccinationonthesymptomsofhospitalisedpatientswithsarscov2deltavariantb16171infection
AT frentiuemilia impactofvaccinationonthesymptomsofhospitalisedpatientswithsarscov2deltavariantb16171infection
AT blanchisophie impactofvaccinationonthesymptomsofhospitalisedpatientswithsarscov2deltavariantb16171infection
AT janssencecile impactofvaccinationonthesymptomsofhospitalisedpatientswithsarscov2deltavariantb16171infection
AT charbonniergabrielle impactofvaccinationonthesymptomsofhospitalisedpatientswithsarscov2deltavariantb16171infection
AT fresseaudrey impactofvaccinationonthesymptomsofhospitalisedpatientswithsarscov2deltavariantb16171infection
AT laurentsimon impactofvaccinationonthesymptomsofhospitalisedpatientswithsarscov2deltavariantb16171infection
AT sandjakianlena impactofvaccinationonthesymptomsofhospitalisedpatientswithsarscov2deltavariantb16171infection
AT casezpierre impactofvaccinationonthesymptomsofhospitalisedpatientswithsarscov2deltavariantb16171infection
AT mahamataba impactofvaccinationonthesymptomsofhospitalisedpatientswithsarscov2deltavariantb16171infection
AT beraudguillaume impactofvaccinationonthesymptomsofhospitalisedpatientswithsarscov2deltavariantb16171infection